[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aging":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,295,0,25,[9,44,79,91,120,153,182,206,232,257,280,337,363,389,415,444,468,496,522,548,574,594,642,668,704],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053680","amyloid-pet-imaging-in-the-baltimore-longitudinal-study-of-aging-100053680",false,"NCT07099053","Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging","Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)","* INCLUSION\u002FEXCLUSION CRITERIA:\n* Participants are men and women 55 years and older drawn from the BLSA sample and thus, represent the gender\u002Fethnic characteristics of this study group. Enrollment is defined as the initial imaging session of the planned longitudinal study.\n* Inclusion criteria: BLSA participants who do not meet exclusion criteria and have had or agreed to have an MRI under the BLSA study.\n* Participants who lack capacity to consent will not be enrolled in the study. If the participant loses capacity to consent over the course of follow-up they will be removed them from the study. Competency to consent is assessed as part of the BLSA visit and we will not include people who are not competent to provide consent.\n\nEXCLUSION CRITERIA:\n\n* Preexisting central nervous system diseases\n* Weight over 300 lbs.\n* Active metastatic cancer (except basal cell cancer)\n* Implanted electronic hearing devices\n* Breast Cancer with radiation treatment\n* Lymphoma\n* Pacemaker\n* Brain tumor\n* Shrapnel\n* Schizophrenia\n* Bipolar disorder\n* Epilepsy\n* Language barrier that makes it difficult to understand participant.\n* Aneurisms greater than 3mm\n* Aneurysm clips\n* Parkinson s disease\u002FPD medications\n* Huntington s disease\n* Severe Endocrinopathy- treated thyroid conditions ok; treated, controlled diabetes ok. (exclude HbA1c over 8 which is poorly controlled diabetes)\n* Diagnosis of dementia or mild cognitive impairment\n* Younger than 55 years of age\n* Pregnancy\n* Ineligible for MRI\n* History of stroke or documented TIAs requiring hospitalization\n* Known brain vascular malformations or adenomas\n* History of significant radiation exposure\n* Those with a Blessed score of 4 or more with the BLSA will be reviewed at a research diagnostic case conference to rule out dementia diagnoses prior to enrollment.",true,"ALL","55 Years","110 Years",{"count":22,"type":23},400,"ESTIMATED","OBSERVATIONAL","Background:\n\nSome people experience cognitive decline as they age. That is, they lose memory, problem-solving, and other mental abilities. Amyloids are groups of proteins that develop in the brain and increase in number as people age. Researchers want to use imaging scans to track amyloids in people s brains over time. Their goal is to find out if any changes are related to cognitive decline or other medical issues.\n\nObjective:\n\nTo learn how amyloids may affect brain structure and function as people age.\n\nEligibility:\n\nPeople aged 55 years and older who are enrolled in the Baltimore Longitudinal Study of Aging.\n\nDesign:\n\nParticipants will have imaging scans and other tests every 1 to 4 years, depending on their age. Those 80 and older will be scanned yearly. These scans will be done during regular BLSA visits.\n\nThe scans will be positron emission tomography and computed tomography (PET CT). Participants will be given fluid through a tube inserted into a vein in their arm. The fluid is a tracer that will cause the amyloids to light up in the images. Then they will lie on a bed with their head inside a PET CT scanner. They will lie still for about 30 minutes.\n\nParticipants will have tests to assess their memory and other mental skills. They will answer questions about their mood and daily life. These tests will take about 40 minutes to complete; they may be done in person or by phone.\n\nParticipants will give a contact number for someone who can answer questions about the participant s daily routine. These questions may be answered in person or by phone.\n\nParticipants will be in this study for 5 years.",[27],"Aging",[29,30],"Amyloid","PET","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":23},"2026-07-16",{"date":39,"type":23},"2029-12-12",{"name":41,"class":42},"National Institute on Aging (NIA)","NIH",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":17,"sex":18,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":43},"100053953","early-time-restricted-eating-combined-with-exercise-in-older-adults-100053953","NCT07695961","Early Time-Restricted Eating Combined With Exercise in Older Adults","Effects of Early Time-Restricted Eating Combined With a Multicomponent Exercise Program on Bone Mineral Density, Gait, Balance, and Fall Risk in Healthy Older Adults: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 60 years or older\n* Community-dwelling and generally healthy older adults\n* Sedentary or moderately physically active\n* Stable body weight during the previous 3 months (no intentional weight loss or gain \\>5%)\n* Able to participate in a supervised exercise program\n* Willing to comply with the time-restricted eating protocol and study procedures\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Diagnosis of osteoporosis requiring pharmacological treatment\n* Severe sarcopenia or major mobility limitations preventing safe exercise participation\n* Cognitive impairment or diagnosed dementia affecting ability to follow instructions\n* Presence of uncontrolled chronic diseases affecting bone metabolism (e.g., advanced renal disease, uncontrolled endocrine disorders)\n* Current use of medications affecting bone metabolism (e.g., corticosteroids, anti-osteoporotic drugs)\n* Participation in another structured exercise or dietary intervention program within the past 3 months\n* Any medical condition that contraindicates moderate-intensity exercise\n* Inability to comply with study protocol or follow-up assessments","60 Years","85 Years",{"count":54,"type":23},44,"INTERVENTIONAL",[57],"NA","This randomized controlled trial aims to investigate the effects of Early Time-Restricted Eating (eTRE) combined with a multicomponent exercise program on bone health, physical function, and fall risk in healthy older adults.\n\nA total of approximately 44 healthy adults aged 60 years and older will be recruited and randomly assigned to one of two groups. The experimental group will follow an Early Time-Restricted Eating schedule combined with a structured multicomponent exercise program. The control group will not receive any dietary timing intervention or structured exercise program and will continue their usual daily lifestyle.\n\nThe intervention will last for 6 months. Participants in the exercise program will perform supervised sessions including resistance training, balance exercises, aerobic activity, and flexibility exercises. The Early Time-Restricted Eating protocol will involve consuming all daily food intake within an early daytime window while maintaining usual dietary quality and adequate energy and nutrient intake.\n\nThe main outcomes of the study include changes in bone mineral density, gait performance, balance, and fall risk. These outcomes will be measured at baseline and after the intervention period.\n\nThis study will provide evidence on whether combining early time-restricted eating with structured exercise can improve musculoskeletal health and functional ability, and reduce fall risk in older adults.",[60,61,27,62,63],"Nutrition","Health and Wellbeing","Time Restricted Eating","Bone Health",[62,65,66,67,68],"Exercise Program","Bone Mineral Density","Gait","Balance","NOT_YET_RECRUITING","2026-07-09",{"date":34,"type":35},{"date":73,"type":23},"2026-06-15",{"date":75,"type":23},"2026-12-30",{"name":77,"class":78},"University of Manouba","OTHER",{"id":80,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":81,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":82,"keywords":83,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":90,"locationsCount":43},"100600558",{"count":22,"type":23},[27],[29,30],"2026-07-01",{"date":86,"type":35},"2026-07-02",{"date":88,"type":23},"2026-07-07",{"date":39,"type":23},{"name":41,"class":42},{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":55,"phases":100,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100636614","tai-chi-intervention-for-balance-function-in-older-adults-predictive-and-modifying-roles-of-circadian-age-100636614","NCT07567976","Tai Chi Intervention for Balance Function in Older Adults: Predictive and Modifying Roles of Circadian Age","Effects of Tai Chi on Balance Function in Community-Dwelling Older Adults: A Randomized Controlled Trial Examining the Predictive and Modifying Roles of Circadian Age, With Multi-Omics and Brain Function Assessments","Inclusion Criteria:\n\n* Aged 55 years or older\n* Community-dwelling\n* Able to walk independently (assistive devices such as canes are permitted)\n* Berg Balance Scale (BBS) score ≤52 at screening\n* Able to understand and follow verbal instructions\n* Willing to wear a wrist accelerometer continuously for 7 days at baseline\n* Willing to accept random group assignment\n* Willing to undergo blood collection during the study\n* Provides written informed consent\n\nExclusion Criteria:\n\n* Regular Tai Chi or yoga practice (more than once per week) within the past 6 months\n* Severe cognitive impairment (Montreal Cognitive Assessment \\[MoCA\\] score \\\u003C20 at screening, or previously diagnosed dementia)\n* Unstable cardiovascular disease (myocardial infarction, stroke, or hospitalization within the past 3 months)\n* Severe musculoskeletal disease that limits exercise participation\n* Neurological diseases affecting balance (e.g., Parkinson's disease, severe peripheral neuropathy)\n* Currently participating in another exercise intervention study\n* Planned surgery or extended absence during the study period\n* Contraindications to functional near-infrared spectroscopy (fNIRS) examination (e.g., scalp injury, metallic implants in the head region)\n* Severe psychiatric illness (e.g., schizophrenia, bipolar disorder)\n* Considered unable to safely participate in moderate-intensity physical activity as judged by the study physician or attending healthcare provider",{"count":99,"type":23},90,[57],"This study investigates the effects of a 12-week Tai Chi intervention on balance function in community-dwelling older adults. Participants are randomly assigned to either a Tai Chi exercise group or a health education control group. The primary outcome is balance function measured by the Berg Balance Scale. Secondary outcomes include physical function, psychological well-being, cognitive function, and sleep quality. The study also explores the predictive and modifying roles of baseline circadian age on intervention outcomes.",[27,103,104],"Postural Balance","Accidental Falls",[106,107,108,109,110,111],"Tai Chi","Tai Ji Quan","Mind-Body Exercise","Older Adults","Fall Prevention","Circadian Rhythm","2026-06-30",{"date":86,"type":35},{"date":115,"type":23},"2026-06-01",{"date":117,"type":23},"2027-03",{"name":119,"class":78},"Zhide Liang",{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":18,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100627087","assessing-biological-aging-in-a-real-world-medical-weight-loss-program-using-the-linage2-clinical-clock-100627087","NCT07444073","Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock","Inclusion Criteria\n\n* Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program.\n* BMI of ≥ 30 kg\u002Fm2 (obesity); OR\n* BMI of ≥ 27 kg\u002Fm2 to \\\u003C 30 kg\u002Fm2 (overweight) in the presence of at least one weight-related comorbid condition e.g. dysglycemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.\n\nExclusion Criteria\n\n* Pregnancy or lactation.\n* Non-ambulatory status, total blindness, complete hearing loss, or inability to speak.\n* Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes.\n* On GLP-1 RA, sulfonylurea or insulin medications for the past 3 months.\n* Active cancer on chemotherapy or immunotherapy.\n* Known hypersensitivity or contraindications to GLP-1 RAs.\n* Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.","40 Years","89 Years",{"count":129,"type":23},440,"This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.",[27,132],"Obesity & Overweight",[134,135,136,137,138,139,140,141,142,143,144],"LinAge2","Biological Age","GLP-1 Receptor Agonist","Semaglutide","Tirzepatide","Weight Management Program","Lifestyle","Real-World Evidence","Cardiometabolic Biomarkers","Body Composition","Prospective Cohort","2026-06-29",{"date":84,"type":35},{"date":115,"type":23},{"date":149,"type":23},"2027-12-31",{"name":151,"class":78},"National University of Singapore",2,{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":18,"minAge":160,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":55,"phases":163,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":43},"100645316","plant-based-diet-in-older-people-what-consequences-for-muscle-health-100645316","NCT07681986","Plant-based Diet in Older People: What Consequences for Muscle Health?","MYOVEG","Inclusion Criteria:\n\n* Men and women aged 65 years and older\n* Body Mass Index (BMI) between 18.5 and 30 kg\u002Fm² (exclusive)\n* Physical activity \\\u003C 3000 MET-min\u002Fweek, assessed using the ONAPS-PAQ questionnaire\n* Laboratory tests compatible with participation in the study\n* Adequate venous status, as assessed by study nurses, allowing catheter placement\n* Willingness to participate in study procedures, including indirect calorimetry, functional tests, and assigned dietary intervention (plant-enriched or standard diet)\n* Affiliation with the French Social Security system\n\nExclusion Criteria:\n\n* Men and women aged 65 years and older\n* Body Mass Index (BMI) between 18.5 and 30 kg\u002Fm² (exclusive)\n* Physical activity \\\u003C 3000 MET-min\u002Fweek, assessed using the ONAPS-PAQ questionnaire\n* Laboratory tests compatible with participation in the study\n* Adequate venous status, as assessed by study nurses, allowing catheter placement\n* Willingness to participate in study procedures, including indirect calorimetry, functional tests, and assigned dietary intervention (plant-enriched or standard diet)\n* Affiliation with the French Social Security system\n* Exclusion period from a previous study or total compensation exceeding €6,000 in the 12 months prior to study initiation (verified through the National Research Volunteer Database)\n* Patients under legal guardianship, curatorship, deprived of liberty, or under judicial protection\n* Claustrophobia","65 Years",{"count":162,"type":23},60,[57],"This randomized, controlled, two-arm clinical study aims to determine how increasing the proportion of plant-based foods in the diet affects skeletal muscle strength, mass and function, protein metabolism, microbiota and key metabolic markers in healthy older men and women. We hypothesize that diets enriched with animal-based foods will maintain maximal quadriceps strength-the primary outcome of the study-more effectively after the 3-month nutritional intervention than plant-based diets. Proteomic analyses will be performed to identify molecular mechanisms and potential muscle biomarkers reflecting metabolic adaptations of skeletal muscle to plant-enriched diets. In addition, metabolic health markers and micronutrient status will be evaluated to better understand the overall health effects of dietary plant-based transition in older adults.",[27],[27,109,167,168,169,170,171,172,143,173],"Plant-Based Diet","Muscle Strength","Skeletal Muscle","Protein Metabolism","Physical Performance","Proteomics","Gut Microbiota","2026-06-26",{"date":86,"type":35},{"date":177,"type":23},"2026-07-20",{"date":179,"type":23},"2030-08",{"name":181,"class":78},"University Hospital, Clermont-Ferrand",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":17,"sex":188,"minAge":189,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":55,"phases":192,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":43},"100644665","early-phase-1-beta3-adrenergic-receptors-and-cardiovascular-function-in-aging-women-100644665","NCT07674680","Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women","Inclusion Criteria:\n\nHealthy women Assigned female at birth 18-70 years of age Body mass index \\\u003C18 or ≥30 kg\u002Fm2\n\nExclusion Criteria:\n\nAssigned male at birth Pregnancy Breastfeeding History of hormone replacement therapy, chemical menopause, or oophor-ectomy Polycystic ovarian syndrome or Primary ovarian insufficiency Current smoking\u002FNicotine use Blood pressure ≥140\u002F90 mmHg Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy Nerve\u002Fneurologic disease Cardiovascular, hepatic, renal, respiratory disease Hypersensitivity to nitroglycerin Diabetes Communication barriers","FEMALE","18 Years","70 Years",{"count":162,"type":23},[193],"EARLY_PHASE1","We hypothesize vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.",[196,27,197],"Women","Menopause","2026-06-23",{"date":145,"type":35},{"date":201,"type":23},"2026-07",{"date":203,"type":23},"2029-05",{"name":205,"class":78},"University of Missouri-Columbia",{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":17,"sex":188,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":55,"phases":217,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":43},"100577459","phase-4-role-of-menopause-in-thermoregulation-100577459","NCT06798571","Role of Menopause in Thermoregulation","The Influence of Estrogen on the Thermoregulatory Responses to Heat Stress in Pre and Postmenopausal Women","Inclusion Criteria:\n\n* Women ages 42-64\n\nExclusion Criteria:\n\n* Chron's disease, diverticulitis, or similar gastrointestinal disease\n* Abnormal resting exercise electrocardiogram (ECG)\n* Tobacco use\n* High-risk determined by the Atherosclerotic Cardiovascular Disease (CVD) Risk Factor\n* Assessment\n* Using hormone therapy\n* Using hormonal contraceptives","42 Years","64 Years",{"count":216,"type":23},24,[218],"PHASE4","The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men.\n\nAging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.",[197,27],[222,223],"Thermoregulation","Heat Stress",{"date":225,"type":35},"2026-06-24",{"date":227,"type":35},"2025-03-01",{"date":229,"type":23},"2026-09-01",{"name":231,"class":78},"Penn State University",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":17,"sex":18,"minAge":160,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":55,"phases":241,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":43},"100571980","phase-1-mtor-inhibitors-in-older-adults-100571980","NCT06727305","MTOR Inhibitors in Older Adults","Characterization of mTOR Inhibitor Pharmacokinetics and Pharmacodynamics in Older Adults .","Inclusion Criteria:\n\n1. Community-dwelling adults\n2. Patients should be 65 Years and older\n3. Patients is able to understand and follow trial procedures\n\nExclusion Criteria:\n\n1. Creatinine clearance \\\u003C30 mL\u002Fmin;\n2. History of chronic liver disease;\n3. Uncontrolled Hypertension (i.e., systolic blood pressure \\>160 mm Hg);\n4. Hemorrhagic central nervous system (CNS) event within 1 year from screening visit;\n5. Thrombotic event (DVT,PE) within 1 year from screening visit if not on anticoagulation;\n6. Planned major surgical procedures;\n7. Cardiovascular diseases ( i.e., admission for heart failure or myocardial infarction within 12 months);\n8. Taking medication that increase or decrease sirolimus blood concentrations;\n9. Other investigational therapy received within 1 month prior to screening visit;\n10. History of dementia; 11 Dependence in any Katz Basic Activities of Daily Living.","80 Years",{"count":162,"type":23},[242,243],"PHASE1","PHASE2","Over the past decades, healthcare systems face significant challenges to meet the needs of an aging population due to progressive debility, functional decline and chronic diseases development. While there is a growing appreciation of the potential impact of mTOR inhibitors on slowing aging processes, preventing chronic disease and prolonging healthy lifespan, a major challenge in developing clinical trials to establish the clinical efficacy of mTOR inhibitors is the absence of pharmacokinetics (PK) and pharmacodynamics (PD) data in older adults. The proposed study will provide the foundation for future clinical trials assessing the role of mTOR inhibitors on aging related indications",[27],[27,247,248],"Geriatic","Disability",{"date":250,"type":35},"2026-06-25",{"date":252,"type":35},"2026-05-11",{"date":254,"type":23},"2027-11-13",{"name":256,"class":78},"University of Texas Southwestern Medical Center",{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":17,"sex":18,"minAge":160,"maxAge":239,"enrollmentInfo":264,"targetDuration":4,"studyType":55,"phases":266,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":43},"100457522","phase-2-the-role-of-sirolimus-in-preventing-functional-decline-in-older-adults-100457522","NCT05237687","The Role of Sirolimus in Preventing Functional Decline in Older Adults","Sirolimus in Older Adults- Randomized Trial Assessing the Improvement in Phenotypic\u002FFunctional Biomarkers of Aging","Inclusion Criteria:\n\n* Patients should be adults 65-80 years\n* Women who are postmenopausal\\* or status post-surgical sterilization only\n* Competent to provide Informed Consent\n\nExclusion Criteria:\n\n* Creatinine clearance \\\u003C30 mL\u002Fmin\n* Underlying chronic liver disease\n* Other investigational therapy received within 1 month prior to screening visit\n* Pulmonary Arterial Hypertension (PAH), mean Pulmonary Arterial Presure(mPAP)\\>30 mm Hg\n* Extrapulmonary physiological restriction (e.g. chest wall abnormality, large pleural effusion)\n* Cardiovascular diseases, any of the following: Myocardial infarction within 6 months, planned coronary artery disease intervention , left ventricular EF \\\u003C45%\n\n  * History of haemorrhagic central nervous system (CNS) event within 1 year from screening visit.\n  * Any of the following within 3 months of screening visit :Haemoptysis or haematuria;Active gastro-intestinal (GI) bleeding or GI - ulcers; Major injury or surgery\n* History of thrombotic event (including, DVT, PE, stroke and transient ischemic attack) within 1 year from screening visit.\n* Other disease that may interfere with testing procedures or in the judgment of the Investigator may interfere with trial participation or may put the patient at risk when participating in this trial.\n* Planned major surgical procedures.\n* Women who are pregnant, nursing, or who plan to become pregnant while in the trial.\n* Concurrent active alcohol or drug abuse.\n* Clinically significant cognitive impairment\n* Functional impairment (defined by ADL status)\n* Patients not able to understand or follow trial procedures",{"count":265,"type":23},10,[243],"Aging is associated with progressive impairment of tissue and organ function, resulting in increased susceptibility to chronic disease, frailty and disability. Currently there are limited treatment options to alter this inevitable process. The proposed work has the potential to identify a new therapeutic intervention to decrease aging-related degenerative processes.\n\nRapamycin or sirolimus is a macrocyclic immunosuppressive drug that inhibits the mammalian target of rapamycin (mTOR). The mammalian target of rapamycin (mTOR) pathway is part of phosphoinositide 3-kinase (PI3K)\u002Fprotein kinase B (AKT)\u002Fmammalian target of rapamycin (mTOR)-dependent pathway which is a fundamentally linked to cell metabolism, proliferation, differentiation, and survival. This pathway is altered in a variety of diseases, including cancers, immunosuppressed states, and fibroproliferative diseases. The mTOR kinase is considered one of the leading regulators of this pathway. Changes in mTOR signaling are closely associated with inflammation, cell growth and survival, leading to the development of chronic diseases. Recent evidence also suggests that mTOR inhibitors are promising modulators of the aging process by slowing the mechanisms of aging at the cellular level. There is a growing appreciation of the potential impact of sirolimus in slowing aging processes and in prolonging healthy lifespan.\n\nThe proposed study addresses critical gaps in our understanding of the safety and efficacy of sirolimus in delaying aging processes and is based on findings in animal studies and incidental clinical observations. The investigators will overcome potential biases with a randomized control trial. The proposed intervention study is intended to improve our insight into clinical outcomes leading to prevention of chronic diseases such as skin cancer and mortality. Our overarching hypothesis is that sirolimus is one of the first pharmacological agents that will impact the aging process and chronic disease development. Specifically, the investigators aim to investigate whether sirolimus can reduce the occurrence or increase in biomarkers of aging processes.",[27],[270,271,272],"aging","sirolimus","prevention",{"date":250,"type":35},{"date":275,"type":35},"2026-03-31",{"date":277,"type":23},"2028-01",{"name":279,"class":78},"Irina Timofte",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":17,"sex":18,"minAge":189,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":55,"phases":290,"briefSummary":291,"conditions":292,"keywords":307,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":43},"100643981","health-ahead-comparative-effectiveness-study-100643981","NCT07669168","Health Ahead Comparative Effectiveness Study","Health Ahead: Sequential Comparative-Effectiveness Studies Toward Automated, Universally Deployable Preventive Health Screening","HACE","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up.\n\nExclusion Criteria:\n\n\\- Age under 18 years.",{"count":289,"type":23},1000000,[57],"The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening - each isolated as a single variable against current practice - on the path toward a fully automated screening system deployable in any environment, including the most isolated and resource-limited communities. Each comparison is evaluated with a common set of engagement, behavior-change, experience, cost, and longitudinal outcome measures, allowing results to accumulate on a consistent yardstick across the life of the platform.\n\nThe first comparison evaluates static versus interactive personalized health report delivery. Subsequent pre-planned comparisons, added by protocol amendment, evaluate mobile community versus fixed laboratory screening; and a hybrid medical-droid plus human-delivery model versus human-only screening. All participants are simultaneously enrolled in the 100-Year Human Aging Study and the Human Observatory Study, contributing individual longitudinal and population-level causal inference data through those protocols.",[293,294,295,296,297,298,27,299,300,301,302,303,304,305,306],"Health Services Accessibility","Rural Health","Medically Underserved Area","Preventive Health Services","Patient Participation","Health Behavior","Cardiovascular Diseases","Metabolic Syndrome","Cognitive Dysfunction","Frailty","Activities of Daily Living","Health Related Quality of Life","Health Equity","Telemedecine",[308,309,310,311,312,305,294,313,314,315,316,143,317,318,319,320,321,135,322,323,324,325,326,327],"Sequential Platform Trial","Interactive Health Report","Health Activation","Mobile Health Screening","Comparative Effectiveness","Medically Underserved","Preventive Medicine","Patient Engagement","Cardiopulmonary Exercise Testing","DEXA","Health Ahead Bus","Mobile Clinic","Automated Screening","Medical Droids","Healthspan","Longevity","Life Expectancy","Chronic Disease","Cost-Effectiveness","Health Services Research","2026-06-20",{"date":250,"type":35},{"date":331,"type":23},"2026-06-09",{"date":333,"type":23},"2099-12-31",{"name":335,"class":336},"William Brandenburg, MD","INDUSTRY",{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":17,"sex":18,"minAge":160,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":346,"conditions":347,"keywords":352,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":359,"leadSponsor":361,"locationsCount":43},"100643936","cognitive-reserve-and-post-fatigue-recovery-in-older-adults-100643936","NCT07667985","Cognitive Reserve and Post-Fatigue Recovery in Older Adults","Determining the Post-Physical and Mental Fatigue Recovery Perspectives of Older Adults Based on Their Cognitive Reserves","Inclusion Criteria:\n\n* being 65 years of age or older,\n* not having any neurological, psychiatric, or systemic disease that would affect one's mental state, and not using any medication for these conditions.\n\nExclusion Criteria:\n\n* Being younger than 65 years old,\n* having an illness or taking medication that affects mental health, or being\n* unable to complete the questionnaires.","90 Years",{"count":22,"type":23},"As people grow older, it is common to experience a drop in physical stamina and memory functions. This can make recovering from daily physical and mental fatigue more difficult, which directly impacts an individual's independent daily life and overall quality of life.\n\n\"Cognitive reserve\" is a term that describes the brain's built-in resilience. Built over a lifetime through education, work, and social activities, a higher cognitive reserve acts like a buffer, helping the brain adapt to stress and aging. While research shows that a high cognitive reserve protects against conditions like dementia, we still do not fully understand how it helps older adults bounce back from normal, everyday physical and mental exhaustion.\n\nThe goal of this study is to investigate how cognitive reserve levels influence how individuals aged 65 and older perceive their recovery after experiencing physical and mental fatigue.\n\nWhat the Study Involves\n\nThe researchers will evaluate participants aged 65 and older to measure their baseline cognitive reserve levels. The study will look closely at how these levels affect the participants':\n\nAbility to cope with daily physical and mental fatigue. Need for rest and rest patterns. Time and ability to return to normal daily activities. Overall perception of their mental and physical recovery. Expected Outcome By understanding this relationship, the study aims to fill a gap in medical literature and help healthcare providers design better, more personalized rehabilitation and lifestyle support programs to improve the quality of life for older adults.",[348,27,349,350,351],"Cognitive Reserve","Mental Fatigue","Fatigue","Recovery of Function",[270,353,354,355],"cognitive reserve","fatigue","Post-Fatigue Recovery","2026-06-19",{"date":250,"type":35},{"date":328,"type":35},{"date":360,"type":23},"2026-09-22",{"name":362,"class":78},"Uşak University",{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":18,"minAge":189,"maxAge":371,"enrollmentInfo":372,"targetDuration":4,"studyType":55,"phases":374,"briefSummary":375,"conditions":376,"keywords":378,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":43},"100641537","experimental-pbt-study-in-fall-prone-subjects-100641537","NCT07654335","Experimental PBT Study in Fall-prone Subjects","Experimental Perturbation-based-training Study in Patients After Stroke and Older Adults","PACE-R","Inclusion Criteria for both arms:\n\n* ability for independent community walking without aids;\n* sufficient cognitive, visual, and communication abilities for study participation.\n\nExclusion Criteria for both arms:\n\n* musculoskeletal impairments;\n* cardiovascular health-related problems;\n* other health conditions that could interfere with the training.\n\nAdditional Inclusion Criteria for post-stroke patients:\n\n* discharge from their regular rehabilitation;\n* at least 6 months after first unilateral cerebral stroke;\n* 18 to 70 years of age;\n* absence of additional neurologic conditions.\n\nAdditional Inclusion Criteria for older adults:\n\n* age 65 to 75 years;\n* no known health-related problems significantly affecting balance and walking.","75 Years",{"count":373,"type":23},50,[57],"The study will investigate safety, usability, feasibility and preliminary efficacy of perturbation-based training in participants post-stroke and older adults with mild balance deficits. Both group will receive three weks of training. The primary outcome measure will be derived from laboratory-induced falls.",[377,27],"Stroke",[104,379,380,381],"Walking","Fall prevention","Perturbation-based training",{"date":225,"type":35},{"date":384,"type":23},"2026-09",{"date":386,"type":23},"2028-09",{"name":388,"class":78},"University Rehabilitation Institute, Republic of Slovenia",{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":17,"sex":18,"minAge":396,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":55,"phases":399,"briefSummary":400,"conditions":401,"keywords":403,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":152},"100569002","testing-effectiveness-of-a-stochastic-noise-stimulator-to-immediately-improve-balance-and-gait-100569002","NCT06688578","Testing Effectiveness of a Stochastic Noise Stimulator to Immediately Improve Balance and Gait","Improvements in Balance and Gait Using a Stochastic Noise Stimulator: Short Term Response","Inclusion Criteria Older (ages 60+) and younger (aged 21-59) participants with no significant health history will be recruited from the community.\n\nExclusion Criteria\n\nAny person with a self-reported history of:\n\n* impaired proprioception\n* significant eye problems\n* neuromuscular disease\n* seizure\n* stroke\n* unmedicated diabetes\n* cardiovascular disease (except controlled hypertension)\n* renal disease or electrolyte imbalance\n* orthopedic disorders such as severe neck or back pain\n* uncontrolled high blood pressure (200\u002F110 or greater)\n* implanted electronic devices (pacemakers, defibrillators, implanted pumps or stimulator devices, cochlear, etc.)\n* psychotic medications or current psychotic symptoms\n* Any other psychiatric condition requiring hospitalization since 1991\n* recent history of alcohol or drug abuse within the past 6 months\n* inability to stand unassisted for 30 seconds or walk unassisted for 6 minutes","21 Years",{"count":398,"type":23},120,[57],"The goal of this intervention study is to determine if a new electronic stimulation device, similar to a TENS can improve balance and make walking easier in older individuals with reduced balance function. The main question aims to answer the following:\n\nCan using the device improve walking speed in older individuals?\n\nParticipants will be asked to perform a number of tasks while wearing the device:\n\nWalk for 6 minutes\n\n* Stand in place while having balance measured (eyes open and closed)\n* Stand on a foam block while having balance measured (eyes open and closed)\n* Sit in a chair that will tilt +\u002F- 20 degrees while wearing goggles that take videos of the participants eyes.",[402,27],"Vestibular Disorder",[404,405,406,407],"Balance and Gait","Stochastic Noise Stimulator","Neural degeneration","neuromodulation",{"date":198,"type":35},{"date":410,"type":23},"2026-09-25",{"date":412,"type":23},"2027-05-31",{"name":414,"class":78},"Massachusetts Eye and Ear Infirmary",{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":17,"sex":18,"minAge":189,"maxAge":371,"enrollmentInfo":423,"targetDuration":4,"studyType":55,"phases":425,"briefSummary":426,"conditions":427,"keywords":430,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":440,"leadSponsor":442,"locationsCount":43},"100641589","effects-of-a-powered-lower-limb-exoskeleton-on-walking-performance-in-older-adults-100641589","NCT07633093","Effects of a Powered Lower-Limb Exoskeleton on Walking Performance in Older Adults","Acute Effects of a Powered Lower-Limb Exoskeleton on Walking Performance in Community-Dwelling Older Adults: A Randomized Crossover Trial","E-WALK","Inclusion Criteria:\n\n* Older adults aged 65 to 75 years who are community-dwelling, independently ambulatory, able to walk independently on level ground, able to maintain standing balance without personal assistance, and able to understand study instructions.\n* Young-adult reference participants aged 18 to 22 years who are healthy university students without known conditions affecting walking or balance.\n\nExclusion Criteria:\n\n* Self-reported neurological disease affecting gait or balance.\n* Major musculoskeletal injury or surgery affecting walking within the previous 6 months.\n* Uncontrolled cardiopulmonary disease.\n* Severe visual or vestibular impairment affecting safe walking.\n* Current lower-limb pain that limits walking.\n* Cognitive impairment that prevents informed consent or protocol adherence.\n* Any condition judged by the study team to make participation unsafe.",{"count":424,"type":23},40,[57],"The goal of this clinical trial is to learn whether a powered wearable lower-limb exoskeleton can improve walking performance in independently ambulatory older adults aged 65 to 75 years.\n\nThe main questions it aims to answer are:\n\n* Does use of a powered lower-limb exoskeleton increase comfortable walking speed over 10 meters?\n* Does use of a powered lower-limb exoskeleton increase average walking speed during a 400-meter walk?\n\nResearchers will compare walking performance in older adults during walking with the powered exoskeleton and walking without the device to determine whether the exoskeleton improves mobility. Young-adult reference participants will also complete walking assessments to provide reference values for walking performance.\n\nParticipants will:\n\n* Attend a screening and familiarization visit.\n* Complete walking assessments with and without the powered exoskeleton in randomized order (older adults only).\n* Perform a 10-meter walk test, a 400-meter walk test, and other physical performance assessments.\n* Complete questionnaires about balance confidence, fear of falling, and device usability.\n* Be monitored for safety events during testing.",[27,379,428,429],"Physical Function","Mobility Limitation",[431,432,433,434,435],"Exoskeleton","Wearable Robotics","Gait Speed","Assistive Technology","Mobility Assistance","2026-06-18",{"date":438,"type":35},"2026-06-22",{"date":84,"type":23},{"date":441,"type":23},"2026-10-01",{"name":443,"class":78},"Hunan Normal University",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":17,"sex":18,"minAge":452,"maxAge":4,"enrollmentInfo":453,"targetDuration":455,"studyType":24,"phases":4,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":43},"100260801","ocean-registry-obesity-and-clock-for-elegant-aging-registry-100260801","NCT02674230","OCEAN Registry: Obesity and Clock for Elegant Aging Registry","OCEAN Registry: Obesity and Clock for Elegant Aging Registry 肥胖控制及生理時鐘之研究計畫","OCEAN","Inclusion Criteria:\n\n* Age ≥ 20 years old\n* Body mass index ≥ 24 kg\u002Fm2\n* For normal subjects, Body mass index \\\u003C 24 kg\u002Fm2\n\nExclusion Criteria:\n\n* No inform consent\n* Use of steroid medications\n* Severe systemic diseases or organ failure with estimated life expectancy of 6 months or less","20 Years",{"count":454,"type":23},2000,"10 Years","This study aims to study the relationships between obesity, circadian rhythm, and aging. The investigators set up a prospective cohort registry for morbid obesity, obesity, and normal subjects with annual follow-up. The cohort aims to investigate the pathophysiological, molecular, genetic, and cellular aspects of the relationships between obesity, circadian deregulation, and impacts on aging. Clinical data, questionnaires, biological material, and molecular signatures will be collected and investigated.",[458,459,27,460],"Obesity","Circadian Dysregulation","Cardiovascular Disease",{"date":198,"type":35},{"date":463,"type":4},"2011-07",{"date":465,"type":23},"2035-06",{"name":467,"class":78},"Chang Gung Memorial Hospital",{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":17,"sex":18,"minAge":189,"maxAge":239,"enrollmentInfo":475,"targetDuration":4,"studyType":55,"phases":477,"briefSummary":478,"conditions":479,"keywords":480,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":43},"100641540","early-phase-1-gait-adaptation-study-100641540","NCT07660601","Gait Adaptation Study","Integrative Training Approach for Inducing Neuroplasticity in Multiple Sclerosis","Inclusion Criteria:\n\n* Age 18 to 80 yrs Clinically definite MS diagnosis Ability to attend to computer screen and follow instructions in English which will be assessed by MiniMental test requiring a participant to score \\>24 (out of 30 max score) Right-handed as determined by research diagnostic criteria of the Edinburgh Handedness Inventory (Oldfield 1971) Self report of normal or corrected-to-normal vision\n\nExclusion Criteria Psychiatric disorders, only those requiring treatment because the medications may affect brain activation Neurological disorder that may affect cognition, balance, and\u002For physical wellness such as brain injury, or stroke.\n\nOrthopedic injuries or neuromuscular disorder that may affect balance or mobility Engagement in other cognitive or physical training program while enrolled in this study Ongoing relapse (new or returning neurological symptoms) or steroid treatment during the 30 days preceding enrollment",{"count":476,"type":23},30,[193],"This pilot study proposes a clinical trial to target treatment of sensorimotor and cognitive deficits in persons with Multiple Sclerosis (pwMS). The proposal has the potential to promote neuroplasticity and induce re-normalization in brain to muscle (cortico-muscular) connectivity (BMC) and within brain connectivity via an integrative training approach. Preliminary data and published work are available to inform specific aspects of the proposed trial, along with the general rationale for exploring the suggested rehabilitation approach. However, there is a gap in research on the effects of training that uses the proposed approach via a clinical trial (of any phase) in pwMS to support the rationale for exploring the suggested rehabilitation training approach. Moreover, there is no pilot data on the training itself in the same population. This study will examine the behavioral deficits and neural characteristics in children with MS and two other related conditions (Myelin Oligodendrocyte Glycoprotein (MOG) and Nueromyelitis Optica Spectrum Disorder (NMOSD)) to understand if they would benefit from rehabilitation training conditions tested in aims 1 and 2. The overall long term goal is to improve rehabilitation training conditions for both adults and children with MS.",[27],[481,482,483,484,485,486,487],"cognition","mobility","impairment","electrophysiology","gait","gait adaptation","daily living","2026-06-16",{"date":438,"type":35},{"date":491,"type":35},"2025-01-31",{"date":493,"type":23},"2028-07-20",{"name":495,"class":78},"Rutgers, The State University of New Jersey",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":17,"sex":18,"minAge":504,"maxAge":52,"enrollmentInfo":505,"targetDuration":4,"studyType":55,"phases":507,"briefSummary":508,"conditions":509,"keywords":514,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":520,"locationsCount":43},"100582854","ketone-ester-and-salt-keas-in-older-adults-100582854","NCT06868719","Ketone Ester And Salt (KEAS) in Older Adults","Ketone Supplementation as a Strategy to Reduce the Negative Health Effects of High Dietary Salt in Older Adults","KEAS-O","Inclusion Criteria:\n\n* Between the ages of 60-85\n* Resting blood pressure no higher than 150\u002F90\n* BMI below 35 kg\u002Fm2 (or otherwise healthy)\n* Free of any metabolic disease (diabetes or renal), pulmonary disorders (COPD, severe asthma, or cystic fibrosis), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular)\n* Do not have any precluding medical conditions that prevent participants from exercising (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis) or giving blood (e.g., blood thinners)\n\nExclusion Criteria:\n\n* High blood pressure - greater than150\u002F90 mmHg\n* Obesity (BMI \\> 30 kg\u002Fm2)\n* History of metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD, severe asthma, \\& cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular).\n* Medical issues that prevent safe exercise (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis)\n* Medical issues that prevent giving blood (e.g., blood thinners).\n* Current smoking, using smokeless tobacco, or vaping (within past 12 months)\n* Current pregnancy","50 Years",{"count":506,"type":23},35,[57],"Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury\u002Fimpaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.",[510,511,27,512,513],"Salt; Excess","Hypertension","Inflammation","Blood Pressure",[513,515,27,512,460],"Salt",{"date":436,"type":35},{"date":518,"type":35},"2025-03-06",{"date":149,"type":23},{"name":521,"class":78},"Indiana University",{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":17,"sex":18,"minAge":189,"maxAge":239,"enrollmentInfo":529,"targetDuration":4,"studyType":55,"phases":531,"briefSummary":532,"conditions":533,"keywords":534,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":544,"leadSponsor":546,"locationsCount":43},"100626775","older-age-and-generalization-100626775","NCT07440017","Older Age and Generalization","Effects of Older Age on the Neural Basis of Memory Generalization","Inclusion Criteria:\n\n* Either aged 18-30 years (young adults) or aged 65-80 years (older adults) (self-report)\n* Fluent in English (self-report)\n* Right-handed (self-report)\n* Cognitively healthy (self report verified by score \\> 24 on Montreal Cognitive Assessment)\n* Self-reported normal or corrected-to-normal vision\n\nExclusion Criteria:\n\n* Self-reported neurological disorder (e.g., Alzheimer's or Parkinson's disease)\n* Self-reported uncontrolled hypertension, diabetes, or thyroid disorder\n* Having conditions or devices that are unsafe for MRI (assessed via imaging center's MRI safety screening form)\n* Self-reported difficulty lying still on one's back for 1-2 hours",{"count":530,"type":23},360,[57],"The goal of this clinical is to learn how the brain supports different kinds of memory decisions in healthy young and older adults. The main question it seeks to answer is: Do older adults make memory decisions by integrating across experiences?\n\nYoung (aged 18-30 years) and older (aged 65-80 years) participants will complete a memory task while undergoing functional MRI to measure their brain responses.\n\nResearchers will compare brain measures of integration in older adults to those of young adults to see if integration increases in older age.",[27],[535,536,537,538,539,540],"cognitive aging","episodic memory","fMRI","generalization","hippocampus","prefrontal cortex",{"date":542,"type":35},"2026-06-17",{"date":73,"type":35},{"date":545,"type":23},"2029-12-31",{"name":547,"class":78},"Caitlin Bowman",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":554,"eligibilityCriteria":555,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":55,"phases":558,"briefSummary":559,"conditions":560,"keywords":563,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":569,"completionDateStruct":570,"leadSponsor":572,"locationsCount":43},"100641643","aging-well-together---getting-to-know-you-better-characterization-of-health-factors-in-people-advancing-in-age-100641643","NCT07651527","Aging Well Together - 'Getting to Know You Better': Characterization of Health FACTors in People Advancing in AGE","BVE-FACTAGE: Aging Well Together - 'Getting to Know You Better': Characterization of Health FACTors in People Advancing in AGE","BVE-FACTAGE","Inclusion Criteria:\n\n* Age 55 or older\n* Affiliation with, or beneficiary of, a social security system\n* No objection to the study\n\nExclusion Criteria:\n\n* Individuals protected by law\n* unable to participate in a clinical trial\n* deprived of liberty",{"count":557,"type":23},4500,[57],"In order to implement effective actions to prevent the loss of autonomy in older adults, which has become a major issue, a crucial first step is to identify the conditions that influence it. Current approaches to health increasingly rely on a comprehensive and multidisciplinary vision, in line with so-called \"socio-ecological\" approaches, which argue that health is influenced by a wide range of interacting factors. However, these interdependencies and interactions are still poorly understood. It therefore seems necessary to move beyond the isolated analyses of risk factors carried out to date and adopt a holistic\u002Fsystemic vision by examining both individual and environmental factors, as well as their interactions, which together can contribute to functional decline or the development of pathologies in older adults and those aging.\n\nThe aim of this study is to identify the relationships between intrapersonal and environmental factors, and their cumulative, moderating, and mediating effects on the health of older adults and those experiencing aging.\n\nTo this end, participants will be asked to complete a series of questionnaires and perform tests on various health-related dimensions. The evaluation criteria are: health, autonomy and quality of life, individual factors (health practices (e.g., physical activity), psychological characteristics (e.g., personal beliefs), socioeconomic status, etc.) and environmental factors (accessibility, living environment).",[27,561,562],"Aging Disorder","Aging, Healthy",[270,564,565,566],"physical activity","diet","environmental factors","2026-06-11",{"date":488,"type":35},{"date":384,"type":23},{"date":571,"type":23},"2031-09",{"name":573,"class":78},"Centre Hospitalier Universitaire de Nice",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":17,"sex":18,"minAge":452,"maxAge":581,"enrollmentInfo":582,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":584,"conditions":585,"keywords":586,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":4,"leadSponsor":593,"locationsCount":43},"100075199","baltimore-longitudinal-study-of-aging-100075199","NCT00233272","Baltimore Longitudinal Study of Aging","The Baltimore Longitudinal Study of Aging (BLSA)","* INCLUSION CRITERIA:\n\nThese criteria pertain to the Screening Visit and Visit 1. If any of these conditions develop after this time, the participant remains in the study. In particular, participants who develop cognitive, motor or psychiatric conditions are retained in the study, although they are excluded from specific testing in which their underlying health condition is an exclusion criteria. Participants that refuse genetic testing and storage at Visit 1 will not be eligible to participate in the study.\n\n* Age greater than or equal to 20 years of age\n* Weigh less than or equal to 300lbs and\u002For body mass index (BMI) is less than or equal to 40\n* Do not have established genetic diseases\n* Are able to perform daily self- care without assistance\n* Are able to walk independently for at least 400 meters without assistance and without developing symptoms\n* Are able to perform normal activities of daily living without shortness of breath (walking or climbing stairs)\n* Do not have cognitive impairment based on screening tests and in the absence of any drug treatment\n* Do not have a history of cardiovascular disease (including angina, myocardial infarction, congestive heart failure, cerebrovascular diseases, uncontrolled hypertension)\n* Do not have a history of diabetes (requiring any medical treatment other than diet and exercise)\n* Do not have active (any activity in the last 10 years) cancer, except for locally limited basal or squamous cell cancer\n* Do not have clinically significant hormonal dysfunction (Laboratory values out of range despite supplementation and\u002For drug treatment)\n* Do not have a history of neurological diseases or birth defects (other than minor anatomical abnormalities, which do not affect physical and\u002For cognitive function)\n* Do not have a history of kidney or liver disease (associated with reduced kidney or liver function)\n* Do not have a history of severe gastrointestinal (G.I.) diseases\n* Do not have muscle-skeletal conditions due to diseases or traumas (that cause pathological weakness and\u002For chronic pain)\n* Do not have a history of severe psychiatric conditions (associated with behavioral problems or requiring chronic medical treatment)\n* Do not have any medical condition that requires absolute and continuous need for long term treatment with antibiotics, corticosteroids, immunosuppressors, H2 blockers and\u002For proton pump inhibitors, or pain medications\n* Do not have important sensory deficits (legally blind and\u002For any condition that precludes the participant from being tested with standard neuropsychological tests or providing informed consent)\n* Able to read and speak English\n* Do not have joint replacements due to arthritic changes (joint replacements due to previous trauma are ok) or do not have 2 or more joint replacements for any reason\n* Do not meet any exclusionary criteria for 3T MRI and agrees to perform the test\n* Agree to genetic (DNA\u002FRNA) sample collection, analysis, and storage at Visit 1\n\nEXCLUSION CRITERIA:\n\nThese criteria pertain to the Screening Visit and Visit 1. If conditions considered as exclusion criteria for study entry develop any time after the this, the participant remains in the study.\n\nExclusion Criteria Based on Laboratory Assessment:\n\n* HIV virus infection\n* Hepatitis B or C\n* Syphilis\n* WBC \\> 12,000\u002FmcrL\n* Platelets \\\u003C 100,000 or \\>600,000 \u002FmcrL\n* Hemoglobin \\\u003C 11 g\u002FdL\n* Creatinine \\>1.5 mg\u002Fdl or calculated creatinine clearance \\\u003C 50 cc\u002Fmin\n* Bilirubin \\> 1.5 mg\u002Fdl (unless higher levels can be ascribed to Gilbert s disease)\n* ALT, AST or alkaline phosphatase twice the normal serum concentration\n* Corrected calcium \\\u003C 8.5 or \\> 10.7 mg\u002Fdl\n* Albumin \\\u003C 3.1 g\u002Fdl","120 Years",{"count":583,"type":23},10000,"Background:\n\n\\- The Baltimore Longitudinal Study of Aging (BLSA) is a clinical research program on human aging that began in 1958. Volunteers of different ages join the study when they are healthy, and have follow-up visits for life. Visits last for multiple days. Participants are evaluated for many physical elements as well as for brain function. Physical tests are given. Information on mood, personality, and social aspects of life is also collected. This program has contributed more than any other research project to our understanding of aging.\n\nObjectives:\n\n\\- To characterize the many aspects of the aging process and learn how people can successfully adapt to aging.\n\nEligibility:\n\n\\- Healthy individuals at least 20 years old.\n\nDesign:\n\n* Participants will receive a booklet and video describing the tests they will take.\n* During a 3-day visit at the study hospital, participants will take the following tests:\n* Urine will be collected for 24 hours. Blood samples will be taken. A small piece of muscle tissue may be collected by a needle.\n* A medical questionnaire and a physical exam will be given.\n* Participants hearts will be tested, including with blood pressure tests and electronic monitors. They will breathe into a tube to test their lungs.\n* Participants will perform several exercises, including treadmill walking.\n* Vision, hearing, and taste will be tested.\n* Bone and joint X-rays may be taken.\n* Imaging tests will be given, such as an MRI.\n* Participants will answer questions to test their mental abilities.\n* Participants will return for follow-up visits every few years for life. The tests listed above will be given at every visit.",[27],[302,587,588],"Disease Processes","Natural History",{"date":590,"type":35},"2026-06-12",{"date":592,"type":35},"2014-02-03",{"name":41,"class":42},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":17,"sex":18,"minAge":189,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":603,"conditions":604,"keywords":615,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":636,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":640,"locationsCount":43},"100641995","human-observatory-study-100641995","NCT07646782","Human Observatory Study","The Human Observatory: A Prospective Individual and Population-Level Study of Aging, Health, and Longevity","HOS","Inclusion Criteria:\n\n* Enrolled in the 100-Year Human Aging Study at any fixed or mobile clinical site; OR completion of online health screener with provision of geographic anchor data and consent.\n\nExclusion Criteria:\n\n* Age under 18 years (current protocol; pediatric amendment planned).",{"count":289,"type":23},"The Human Observatory Study is a prospective observational and ecological surveillance study building a continuously-updating world model for human health, disease, and death at the individual and population level. Individual multi-system clinical data from enrolled participants are linked to a continuously-ingested ecological data infrastructure spanning environmental exposures, social determinants, genealogical and family history records, mortality data, and population health databases at geographic resolutions from home address to global scale and beyond. The resulting model generates individual screening recommendations informed by population-level causal estimates, and population-level causal forecasts anchored by present-timepoint individual clinical biology. Thus creating a feedback architecture designed to improve both simultaneously.",[27,605,606,324,299,607,301,300,302,608,609,610,303,304,611,612,613,305,614],"Mortality","All-cause Mortality","Neoplasms","Musculoskeletal Disease","Neurodegenerative Disease","Dementia","Disability Physical","Environmental Exposure","Occupational Diseases","Social Determinants of Health",[616,617,618,619,620,621,622,623,624,625,626,627,628,305,629,630,316,143,314,322,631,632,633,634,635],"longevity","biological aging","causal inference","life expectancy","exposome","Environmental Health","Social Determinants","Genealogy","Family History","Human Family Tree","Population Health","Neighborhood Health","Geographic Health Disparities","Mortality Prediction","Biomarker Validation","Functional Decline","Centenarian","Space Medicine","Aerospace Medicine","World Model",{"date":73,"type":35},{"date":638,"type":35},"2026-04-25",{"date":333,"type":23},{"name":641,"class":336},"Longevity Metrics, Inc.",{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":4,"eligibilityCriteria":648,"healthyVolunteers":17,"sex":18,"minAge":189,"maxAge":4,"enrollmentInfo":649,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":650,"conditions":651,"keywords":657,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":663,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":667,"locationsCount":43},"100636291","100-year-human-aging-study-100636291","NCT07563777","100-Year Human Aging Study","100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up\n\nExclusion Criteria:\n\n* Age under 18 years",{"count":289,"type":23},"The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed and mobile clinical sites to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.",[27,652,653,605,300,299,301,654,607,302,303,655,611,656,610],"Aging Well","All-Cause Mortality","Musculoskeletal Diseases","Health-Related Quality of Life","Neuro-Degenerative Disease",[323,316,143,314,658,629,631,322,324,659,660,661,630,662,626,632],"Surrogate Endpoint Validation","Biological Aging","Preventive Screening","Longitudinal Cohort","Human Performance",{"date":567,"type":35},{"date":665,"type":35},"2025-02-09",{"date":333,"type":23},{"name":641,"class":336},{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":4,"eligibilityCriteria":674,"healthyVolunteers":17,"sex":18,"minAge":160,"maxAge":4,"enrollmentInfo":675,"targetDuration":677,"studyType":24,"phases":4,"briefSummary":678,"conditions":679,"keywords":685,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":697,"startDateStruct":698,"completionDateStruct":699,"leadSponsor":701,"locationsCount":703},"100633930","italian-validation-of-the-dna-scale-and-its-correlation-with-neurocognitive-variables-100633930","NCT07533084","Italian Validation of the dNA Scale and Its Correlation With Neurocognitive Variables","Italian Validation of the Dynamic Neurocognitive Adaptation (dNA) Scale and Its Correlation With Neurocognitive Variables","Inclusion Criteria (Stage #1):\n\n* Individuals aged ≥ 65 years residing in Italy;\n* Cognitively healthy individuals (HC);\n* Individuals with subjective memory complaints (SMC);\n* Individuals with mild cognitive impairment (MCI);\n* Individuals with probable Alzheimer's disease (AD).\n\nInclusion criteria (Stage #2 \\& Stage #3):\n\n* Individuals aged ≥ 65 years residing in Italy;\n* Cognitively healthy individuals (HC);\n* Individuals with subjective memory complaints (SMC);\n* Individuals with mild cognitive impairment (MCI);\n* Individuals with probable Alzheimer's disease (AD);\n* Individuals with Alzheimer's disease or other forms of dementia;\n* Individuals suffering from mental disorders clinically diagnosed.\n\nCognitively healthy individuals (HC):\n\n* MMSE score ≥24, or alternatively MoCA score ≥26;\n* No diagnosis of depression, MCI or any form of dementia;\n* Episodic memory performance within the normal range (Wechsler Memory Scale Logical Memory II ≥9 for 16 years of schooling or more; ≥5 for 8-15 years of schooling, ≥3 for 0-7 years of schooling; or alternatively for Prose Memory Test with scores ≥9 for ≥16 years of schooling → ≥5 items in immediate or delayed recall; ≥5 for 8-15 years of schooling → ≥3-4 items in immediate or delayed recall; ≥3 for 0-7 years of schooling → ≥2 items in immediate or delayed recall)\n\nIndividuals with Subjective Memory Complaints (SMC):\n\n* MMSE score ≥24, or alternatively MoCA score ≥26;\n* A significant memory impairment, reported by the subject, a family member, or the clinician;\n* No diagnosis of depression, MCI or any form of dementia;\n* Episodic memory performance within the normal range on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling (≥9 for 16+ years of schooling, ≥5 for 8-15 years of schooling, ≥3 for 0-7 years of schooling) or, alternatively, on the Prose Memory Test (with scores ≥9 for ≥16 years of schooling → ≥5 items in immediate or delayed recall; ≥5 for 8-15 years of schooling → ≥3-4 items in immediate or delayed recall; ≥3 for 0-7 years of schooling → ≥2 items in immediate or delayed recall)\n\nIndividuals with Mild Cognitive Impairment (MCI):\n\n* MMSE score between 19 and 23 inclusive (alternatively MoCA);\n* A decline in memory reported by the subject, a family member, or the clinician;\n* No diagnosis of depression or affected by any form of dementia, with preserved ability in activities of daily living;\n* Objective episodic memory loss on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling.\n\nIndividuals with probable Alzheimer's disease (AD):\n\n* Insidious onset with atypical course: some criteria for probable AD are met, but the onset of symptoms may have been sudden, or there is a lack of objective evidence of progressive cognitive decline;\n* Mixed etiology presentation: All criteria for probable AD are met, with concomitant cerebrovascular disorders, or the presence of features typical of another dementia or the evidence of other neurological disorders or non-neurological comorbidities;\n* A decline in performance compared to the previous level of functioning is evident, as also described by a caregiver (often a family member)\n* Onset with memory disturbances, defined as difficulty learning new information or recalling it;\n* Onset with non-mnemonic symptoms (language symptoms, particularly difficulty finding the correct words; visuospatial symptoms: perceptual deficits characterized by failure to recognize objects, people, or written words; executive symptoms: difficulties with reasoning and critical thinking);\n* MMSE score \\\u003C 23 (alternatively MoCA \\\u003C 25);\n* Objective episodic memory loss on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling.\n\nExclusion criteria (Stage #1):\n\n* Individuals aged \\\u003C 65 years;\n* Individuals not residing in Italy;\n* Individuals with depression or other psychiatric disorders;\n* Individuals with forms of dementia other than Alzheimer's disease.",{"count":676,"type":23},265,"1 Year","The goal of this experimental multicentric intervention study is to validate, in Italian, the dynamic Neurocognitive Adaptation (dNA) Scale, which has already been validated in English, among a healthy elderly population (aged 65 and older) residing in Italy and patients with dementia or Alzheimer's Disease. dNA is a questionnaire designed to assess both current and past levels of engagement in physical, cognitive, creative, and social activities.\n\nThe study aims to recruit a total of 265 participants with mild cognitive impairment, subjective memory complaints, or dementia. These participants will be distributed among the 8 recruitment centers. Neuropsychological data, subjective measures, and MRI data will be collected and analyzed to address the following research questions: 1) Is there a positive correlation between scores on the dNA Scale and cognitive efficiency, as reflected in neuropsychological measures, such as episodic memory and executive functions? 2) Is there a correlation between dNA scores and improved functional connectivity within neural networks, such as the Default Network (DN)?\n\nParticipants recruited at the participating clinical centers will undergo:\n\n* A clinical interview, during which demographic and medical history information will be collected. The dNA Scale will be administered, along with a questionnaire assessing adherence to dietary habits typical of a Mediterranean diet (14-Item Mediterranean Diet Adherence Screener; MEDAS).\n* A neuropsychological assessment, aimed at evaluating general cognitive function with a particular focus on episodic memory and executive functions. The following tests will be administered: Mini-Mental State Examination (MMSE) or, alternatively, Montreal Cognitive Assessment (MoCA); Rey Auditory Verbal Learning Test (RAVLT); Trial Making Test (TMT) Form B; Digit Span Forward and Backward (WAIS or WAIS-III); and the Stroop Test.\n* Self-report questionnaires designed to assess depressive symptoms using the Geriatric Depression Scale (GDS) and anxiety symptoms using the Geriatric Anxiety Scale (GAS) (or alternatively the State-Trait Anxiety Inventory, STAI). Finally, the Cognitive Reserve Index Questionnaire will be administered to estimate Cognitive Reserve (CRIq).\n* Where available, MRI data previously acquired for clinical or diagnostic purposes will be included in the study and analyzed by the principal investigator.",[680,27,681,610,682,683,684],"Active Aging Individuals Aged 65 and Over","Mild Cognitive Impairment (MCI)","Dementia Alzheimer Type","Subjective Memory Complaints","Probable Alzheimer's Disease",[686,687,688,689,690,691,272,692,693,694,695,696,270],"activities","habits","lifetime protective factors","adaptation","dynamic","neurocognitive","reserve","resilience","resistance","validation","well-being",{"date":567,"type":35},{"date":384,"type":23},{"date":700,"type":23},"2027-11-27",{"name":702,"class":78},"Neuromed IRCCS",8,{"id":705,"slug":706,"hasResults":12,"nctId":707,"briefTitle":708,"officialTitle":708,"acronym":4,"eligibilityCriteria":709,"healthyVolunteers":17,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":710,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":712,"conditions":713,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":716,"lastUpdatePostDateStruct":717,"startDateStruct":718,"completionDateStruct":719,"leadSponsor":721,"locationsCount":4},"100643096","research-project-on-the-interaction-between-immune-function-and-infectious-diseases-in-older-adults-and-the-development-of-prevention-and-control-strategies-100643096","NCT07644962","Research Project on the Interaction Between Immune Function and Infectious Diseases in Older Adults and the Development of Prevention and Control Strategies","Inclusion Criteria:\n\n\\- General Cohort Inclusion Criteria\n\n1. Adults aged 60 years or older who are in generally good health, defined as having no severe organ dysfunction that significantly affects daily living activities (e.g., decompensated heart, liver, or kidney failure), adequate nutritional status (without significant wasting or malnutrition), and the ability to communicate and comply with study procedures.\n2. Male or female.\n3. Able to understand the study and voluntarily provide written informed consent.\n\nInfection Cohort Inclusion Criteria\n\n1. Adults aged 60 years or older, regardless of sex.\n2. Patients with an infectious disease diagnosed by a qualified clinician.\n\nExclusion Criteria:\n\n* General Cohort Exclusion Criteria\n\n  1. Refusal to participate in this study.\n  2. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.\n\nInfection Cohort Exclusion Criteria\n\n1. Final primary diagnosis is a non-infectious disease (e.g., connective tissue disease, malignancy, or other non-infectious conditions).\n2. Positive culture results determined by the treating clinician to represent colonization or contamination rather than true infection.\n3. Refusal to participate in this study.\n4. Critically ill patients or those unable to cooperate with specimen collection procedures.\n5. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.",{"count":711,"type":23},23000,"As population aging accelerates, infectious diseases have become a major factor affecting the health, quality of life, and survival outcomes of older adults. Immunosenescence, chronic low-grade inflammation (inflammaging), and dysbiosis of the respiratory and gut microbiota are considered important mechanisms underlying increased susceptibility to infection and a higher risk of severe disease in older adults. However, the interactions among these factors and their impact on infection-related outcomes remain incompletely understood.\n\nBuilding upon a previously established pilot cohort of older adults, this study aims to further identify and validate key biological characteristics and risk factors associated with infectious diseases through large-scale population follow-up. A large prospective cohort of older adults will be established, while retrospective healthcare data collected since 2019 will also be integrated. Demographic information, comorbidities, medication history, infection-related clinical data, and biological specimens, including blood, urine, fecal, and respiratory samples, will be collected for long-term longitudinal follow-up. By integrating immunological assessments, immune repertoire analyses, microbiome profiling, and other multi-omics technologies, this study will systematically evaluate the effects of immunosenescence, respiratory and gut microbiome alterations, and environmental and climatic factors on the occurrence, severity, and prognosis of infectious diseases in older adults. The study aims to identify key biomarkers and microbial signatures associated with infection risk and to develop risk prediction and early warning models for infectious diseases in older adults, thereby providing scientific evidence for precision prevention, optimized clinical management, and public health decision-making in aging populations.",[714,715,27],"Infectious Diseases","Immunosenescence","2026-06-08",{"date":590,"type":35},{"date":331,"type":23},{"date":720,"type":23},"2029-12-30",{"name":722,"class":78},"Huashan Hospital"]